Loading...
•
Dec 31, 2020
Taysha Gene Therapies Q4 2020 Earnings Report
Reported full-year financial results and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported its full-year 2020 financial results, highlighting significant progress in its pipeline initiatives, technology platforms, and manufacturing strategy. The company anticipates a transformational year in 2021 with upcoming clinical data and trial initiations.
Completed one of the fastest seed to IPOs in biotech history.
Advanced pipeline initiatives, next-generation technology platforms and manufacturing strategy.
Expects to report first-in-human clinical data for TSHA-101 in GM2 gangliosidosis and initiating Phase 1/2 trials in CLN1 disease, Rett syndrome and SURF1-associated Leigh syndrome in 2021.
Grown from a handful of employees at inception to approximately 80 as of the end of February.
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Taysha Gene Therapies anticipates several milestones in 2021, including clinical data reports, IND submissions, and trial initiations across its gene therapy programs. The company also plans to advance its technology platform and expand its manufacturing capabilities.
Positive Outlook
- Report preliminary Phase 1/2 safety and biomarker data (Queen’s University trial) in the second half of 2021
- Submit an Investigational New Drug (IND) application in the U.S. in the second half of 2021
- Initiate Phase 1/2 clinical trial in the U.S. in the second half of 2021
- Report preliminary Phase 1/2 clinical data (Queen’s University trial) by year-end 2021
- Initiate a Phase 1/2 clinical trial in the second half of 2021 with commercial-grade GMP material
Challenges Ahead
- Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties
- Risks regarding our business are described in detail in our Securities and Exchange Commission filings
- Such risks may be amplified by the impacts of the COVID-19 pandemic.
- The company had a net loss of $60.0 million for the year ended December 31, 2020
- Change in fair value of preferred stock tranche liability (17,030 )